V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira, K. Ushijima, J. Sakata, K. Yonemori, Y. Kim, E. Guerra, U. Sanli, M. McCormack, J. Huang, A. Smith
{"title":"一项多中心、开放标签、随机、3期研究,比较lenvatinib联合派姆单抗与医生选择治疗晚期子宫内膜癌患者的疗效和安全性:study 309/keynote-775","authors":"V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira, K. Ushijima, J. Sakata, K. Yonemori, Y. Kim, E. Guerra, U. Sanli, M. McCormack, J. Huang, A. Smith","doi":"10.1136/ijgc-2021-igcs.8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"12","resultStr":"{\"title\":\"O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775\",\"authors\":\"V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira, K. Ushijima, J. Sakata, K. Yonemori, Y. Kim, E. Guerra, U. Sanli, M. McCormack, J. Huang, A. Smith\",\"doi\":\"10.1136/ijgc-2021-igcs.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19692,\"journal\":{\"name\":\"Oral abstracts\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2021-igcs.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775